ArticleFrontiers in pharmacology2022

Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease.

Tianyu Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.